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Abstract
Germ line mutations of the LKB1 tumor suppressor
gene lead to Peutz–Jeghers syndrome (PJS) with a
predisposition to cancer. Previous reports suggest
that inactivation of this tumor-suppressor gene plays a
role in the pathogenesis of gastrointestinal hamarto-
mas as well as several cancers, including adenocarci-
noma of the pancreas. Here, we have shown that LKB1
gene is silenced in the pancreatic cancer cell line
AsPC-1, but can be recovered by treatment with
the methylation inhibitor, 5-aza-2V-deoxycytidine
(5aza2dC). Restoring the level of LKB1 through gene
transfer initiated mitochondria-mediated apoptosis in
AsPC-1cells, asevidencedby the releaseofcytochrome
c from the mitochondria. By confocal microscopy as
well as biochemical fractionation, we demonstrate that
LKB1 is present in the nuclear and mitochondrial
compartments of pancreatic cancer cells. Our observa-
tions also indicate that although functional p53 is
absent, the p53 kin, p73, is inducible by doxorubicin in
AsPC-1 cells. This suggests that LKB1-induced apopto-
sis is p53 independent but might be p73-mediated in
the pancreatic tumor cell line, AsPC-1.
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Introduction
Peutz–Jeghers syndrome (PJS) is an autosomal domi-
nantly inherited disease [1,2]. Hamartomatous polyps of
the gastrointestinal tract and melanin pigmentation of the
lips and buccal mucosa characterize this syndrome [1,2].
Patients with PJS have an increased risk of developing
cancers of a variety of tissues [3–11]. The causative
gene of PJS has been found to be LKB1/STK11 [7,12].
By linkage analysis, LKB1/STK11 was mapped to chro-
mosome 19p13.3 [12]. LKB1 is widely expressed in adult
human tissues except in Xenopus, where expression of its
homologue is restricted to early embryogenesis [13]. The
presumptive wild-type allele was noted to be lost in the
hamartomas, thus suggesting that LKB1 is a potential
tumor suppressor [4,14]. The human LKB1 gene encodes
a serine/threonine protein kinase that is deficient in
the majority of patients with PJS. Besides homozygous
deletion, an alternative mechanism for the inactivation of
LKB1 gene in sporadic neoplasms is promoter hypermethy-
lation [9].
Recently, the mechanism of action of LKB1 has begun to
emerge. It has been shown that LKB1 is overexpressed in
apoptotic cells of the small intestine [15]. Based on this, the
apoptosis-inducing ability of LKB1 was investigated. Interest-
ingly, the ectopic overexpression of LKB1 induced apoptosis in
a kinase-dependent manner in cells harboring functional p53
[15]. On the other end, the overexpression of LKB1 in LKB1-
deficient cells was shown to suppress cell growth accompanied
by a G1 cell cycle arrest with the induction of p21 promoter [16].
Both G1 arrest and the induction of p21 promoter were found to
be p53-dependent.
Moreover, recent in vitro cloning studies identified Brg1, a
component of chromatin remodeling complex, to be an inter-
acting protein of LKB1, and LKB1 kinase activity was shown to
be required for Brg1-dependent growth arrest [17]. Besides,
studies on LKB1 knockout mice revealed its role in regulating
the expression of the vascular endothelial growth factor, thus
suggesting the involvement of LKB1 in angiogenesis [18].
LKB1 heterozygous knockout mice developed gastrointestinal
polyps resembling the histologic characteristics of PJS [19] as
well as hepatocellular carcinoma [5].
In our laboratory, we were primarily interested in analyz-
ing the expression of LKB1 in pancreatic cancer cells. Our
result reveals the presence of LKB1 in most of the cell lines
tested except in a human pancreatic adenocarcinoma cell
line, AsPC-1, where LKB1 is silenced by promoter hyper-
methylation. Furthermore, we have observed that overex-
pression of LKB1 can initiate programmed cell death in a
mitochondria-dependent manner in the LKB1/p53 null cell
line, AsPC-1. We propose that although LKB1-induced
apoptosis is p53-independent in AsPC-1 cells, it might be
regulated by the p53 kin, p73 [20].
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Materials and Methods
Reagents
Goat polyclonal antibody against human LKB1, rabbit
polyclonal antibody against human p73, and mouse mono-
clonal antibody against human p53 were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Mouse mono-
clonal h-actin and cytochrome c antibodies were obtained
from Sigma (St. Louis, MO) and Pharmingen (San Diego,
CA), respectively. Cytochrome c oxidase subunit I (COX I)
antibody was from Molecular Probes (Eugene, OR). Cas-
pase inhibitor z-VAD was purchased from R&D Systems
(Minneapolis, MN).
Cells and Culture Conditions
Human pancreatic cancer cell lines MIA PaCa-2, PANC-
1, AsPC-1, BxPC-3, Hs 766T, SU 8686, and CFPAC-1 were
grown in RPMI supplemented with 10% FBS and 50 Ag/ml
gentamicin at 37jC in a 5% CO2 humidified atmosphere.
Transient transfection of the GFP-LKB1 construct in AsPC-1
cells was performed by calcium phosphate coprecipitation
method [21].
Assessment of the Level of Expression of LKB1 and p53
Protein
Total cellular proteins were extracted as described before
[22,23]. After normalization for total protein content, the
resulting lysate was subjected to sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and immu-
noblotting [22,23]. Immunodetection was accomplished by
enhanced chemiluminescence kit available from Amersham/
Pharmacia Biotech (Piscataway, NJ).
Subcellular Fractionation
Isolation of a highly enriched mitochondrial fraction as
well as cytosolic fraction of GFP-LKB1–transfected AsPC-1
Figure 1. Epigenetic inactivation of LKB1 in pancreatic cancer. Panel A: Loss of LKB1 in the pancreatic cancer cell line, AsPC-1. Lane 1: MIA PaCa-2; lane 2:
BxPC-3; lane 3: SU 8686; lane 4: AsPC-1; lane 5: Hs766T; lane 6: CFPAC-1; and lane 7: PANC-1. Total cellular proteins were isolated followed by fractionation on
SDS-PAGE. Proteins were electrophoretically transferred onto a nitrocellulose membrane. Immunoblotting was performed using antibody against human LKB1.
Panel B: Restoration of LKB1 in AsPC-1 cells by treatment with the demethylating agent, 5-aza-2 V-deoxycytidine. AsPc-1 cells were treated with 3 lM 5aza2dC for
the indicated period of time. Cellular extracts were immunoblotted with both LKB1 and b-actin antibodies.
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Figure 2. Overexpression of LKB1 promotes apoptosis in the LKB1 null cell line, AsPC-1. Panel A: Assessment of apoptosis by DAPI staining. Indicated
expression constructs were transfected into AsPC-1 cells. Sixteen hours posttransfection, cells were either treated with 500 nM z-VAD or vehicle solvent and were
incubated further a for 24 hours. Cells were fixed with 4% p-formaldehyde followed by morphological determination of apoptosis by DAPI staining. Approximately
200 GFP-positive cells were scored in each test. Percent of apoptosis was calculated as the percent of GFP-positive cells containing condensed nuclei with respect
to the total number of cells carrying GFP fluorescence. The results are exhibited as meanFSD. Panel B: Immunofluorescence detection of cytochrome c release
from mitochondria in GFP-LKB1– transfected cells. (I) CY3 fluorescence in cells labeled with mouse monoclonal cytochrome c antibody as primary and CY3-
conjugated antimouse IgG as secondary. (II) GFP fluorescence pattern in GFP-LKB1– transfected cell. (III) DAPI staining of nuclei of both transfected and
untransfected cells.
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cells was carried out using a kit available from BioVision
(Mountain View, CA). Briefly, 5107 cells were suspended
in 1 cytosolic extraction buffer mix containing DTT and
protease inhibitors. Following incubation on ice for 10
minutes, cells were homogenized in ice-cold Dounce
homogenizer. The homogenate was centrifuged at
700g for 10 minutes at 4jC. The pellet was collected
as crude nuclei. The supernatant of this step was further
centrifuged at 10,000g for 30 minutes at 4jC. The
resulting supernatant was collected as cytosol fraction.
The pellet was resuspended in mitochondrial extraction
buffer containing DTT and protease inhibitors and was
saved as mitochondrial fraction.
Analysis of Cell Death
Chromatin condensation was determined by DAPI fluo-
rescence [22]. Cells were fixed in chilled methanol/acetone
(1:1) for 10 minutes at room temperature and permeabilized
with 0.5% Tween 20 in PBS for 5 minutes. Subsequently,
cells were mounted in a fluid containing 2 Ag/ml DAPI (Vector
Laboratories, Burlingame, CA). A Nikon (Huntley, IL) Eclipse
E600 Fluorescence microscope was used to visualize
nuclear stain.
Immunofluorescence Microscopy
Cells were fixed in 4% paraformaldehyde followed by
permeabilization with 0.5% Triton X-100. Blocking was
Figure 3. Subcellular localization of ectopically expressed LKB1 in AsPC-1 cells. Panel A: Confocal images of LKB1-transfected AsPC-1 cells. Cells at
subconfluent density were transfected with GFP-LKB1. Twenty-four hours after transfection, cells were fixed with 4% p-formaldehyde and processed for
immunostaining using mouse monoclonal COX I primary antibody (mitochondrial marker) and CY3-conjugated antimouse secondary antibody. Cells were further
stained with TOPRO-3 to visualize nuclei. (I) GFP fluorescence distribution in the cell. (II) COX I staining as evidenced by CY3 fluorescence. (III) TOPRO staining
of the nuclei. (IV) Merging of nuclear and mitochondrial staining. (V) Differential interference contrast (DIC) image of the cell. (VI) Merging of GFP fluorescence with
the mitochondrial and nuclear stain. Panel B: Western blots of purified mitochondrial fraction from AsPC-1 cells transfected with GFP-LKB1 cDNA. Lane 1: pEGFP-
C2 vector-transfected control; and lanes 2 and 3: GFP-LKB1– transfected. Lanes 1 and 2 were probed with anti-GFP antibody and lane 3 with anti-LKB1 antibody.
Panel C: Western blots of cytosol and nuclear extracts of LKB1-transfected AsPC-1 cells. Lanes 1 and 3: vector control; and lanes 2 and 4: GFP-LKB1–
transfected.
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done with 4% normal goat serum. Next, the slides were
incubated in either mouse monoclonal cytochrome c or
COX I antibody. Following brief washes, the cells were
incubated with CY3-conjugated antimouse IgG (Jackson
Immunoresearch Laboratories, West Grove, PA). Subse-
quently, cells were washed and stained with TOPRO-3
(Molecular Probes, Eugene, OR). Images were captured
on either SP2 Leica Confocal microscope (Bannockburn,
IL) or Nikon Eclipse E600 fluorescence microscope
(Huntley, IL).
Results
Epigenetic Inactivation of LKB1 in the Human Pancreatic
Cancer Cell Line, AsPC-1
Initially, we were interested in testing whether cell lines
derived from human pancreatic cancer express LKB1. As
evident in lane 4 of Figure 1A, of seven pancreatic cancer cell
lines tested, the expression of LKB1 is lost in the human
pancreatic adenocarcinoma line, AsPC-1. The loss of
expression of LKB1 by methylation in cancer cells has been
reported in the literature [9]. In order to understand whether
LKB1 is silenced by methylation in AsPC-1 cells, we inves-
tigated the effect of treatment with demethylating agents
such as 5-aza-2V-deoxycytidine (5aza2dC). The treatment of
3 AM 5aza2dC for a period of 7 to 8 days can restore the
expression of LKB1 (Figure 1B), indicating the possibility of
inactivation of the LKB1 gene by promoter hypermethylation
in AsPC-1 cells.
LKB1-Mediated Apoptosis is Mitochondria-Dependent
The involvement of LKB1 in the induction of apoptosis
has been previously implicated in fibrosarcoma cell lines
expressing functional p53 [15]. Here, we were interested
in understanding the consequences of LKB1 overexpres-
sion in AsPC-1 cells harboring silenced LKB1 genes. For
this purpose, AsPC-1 cells were transfected with either
GFP control vector or GFP-tagged LKB1 expression con-
structs. Indeed, overexpression of LKB1 induced signifi-
cant cell death in contrast to vector control. Approximately
75% of GFP-positive cells demonstrated the presence
of condensed nuclei as evident from DAPI staining.
In order to ascertain that LKB1-induced apoptosis in
pancreatic cancer cells is caspase-dependent, GFP-LKB1–
transfected cells were treated with a broad-spectrum
caspase inhibitor, z-VAD, 16 hours posttransfection. Due
Figure 3. (continued)
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to z-VAD treatment, the extent of GFP-LKB1–transfected
cells exhibiting nuclear condensation was significantly
reduced (Figure 2A).
Mitochondria serve as an important sensor and ampli-
fier in intracellular death signaling pathways. Cytochrome
c is normally sequestered in the mitochondria and is
Figure 4. Functional p73, but not functional or mutant p53, is present in AsPC-1 cells. Panel A: Western blot showing p53 level in pancreatic cancer cells. Panel B:
Functional p53 cannot be induced in AsPC-1 cells by doxorubicin contrary to SK Mel 147 cells. Metastatic melanoma cells SK Mel 147 containing functional p53
were used as positive control. Both cells were challenged with 0.3 lM doxorubicin for indicated time periods. Western blot with p53 antibody that recognizes both
wild and mutant forms of p53 is presented. Panel C: Doxorubicin can induce functional p73 in AsPC-1 cells. AsPC-1 cells were treated with 0.3 lM doxorubicin for 4
to 16 hours. Cell lysate was subjected to immunoblot analysis with p73 antibody.
372 LKB1 Mediated Apoptosis in Pancreatic Cancer Qanungo et al.
Neoplasia . Vol. 5, No. 4, 2003
released into the cytosol during early apoptosis due to
disruption of the outer mitochondrial membrane. To ask
whether LKB1 induces apoptosis in AsPC-1 cells in a
mitochondria-dependent manner through cytochrome c
release, we performed immunofluorescence staining of
LKB1-transfected cells using cytochrome c antibody. The
micrographs revealed a typical mitochondrial pattern [24] in
control cells (not GFP-positive) due to lack of apoptosis.
This pattern is altered to a diffused staining typical of
apoptosis [24], implicating the release of cytochrome c from
mitochondria of GFP-LKB1–transfected cells (Figure 2B,
Panels I and II ).
Subcellular Localization of LKB1
In order to assess the localization of overexpressed
LKB1, immunofluorescence microscopy as well as biochem-
ical fractionation studies were undertaken. The confocal
images demonstrate the presence of LKB1 in both nucleus
and mitochondria (Figure 3, Panel A: I–VI ). The studies
using mitochondrial markers such as COX I antibody indicate
the colocalization of GFP stain with COX I (Panel A: I and II).
The staining of the nucleus with TOPRO-3 demonstrates the
appearance of LKB1 also in the nuclear compartment (Panel
A: I– IV ). Panel A, VI of Figure 3 clearly shows the merging
of nuclear and mitochondrial stains with GFP fluorescence in
transfected AsPC-1 cells. Furthermore, biochemical fractio-
nation also reveals the dual localization of GFP-LKB1 in
mitochondria as well as in nuclei (Figure 3, Panels B and C).
Apparently, in GFP-LKB1–positive cells, which undergo
apoptosis, a pool of LKB1 is translocated to the mitochondria
to initiate apoptosis, as observed earlier [15].
LKB1-Induced Apoptosis in AsPC-1 Cells is p53-
Independent But Might Be Regulated by the p53 kin, p73
The mutations in the p53 tumor suppressor gene are
extremely common in most human cancers. p53 promotes
cell cycle arrest or apoptosis in response to cellular damage.
In order to evaluate whether LKB1 processes p53-
dependent or p53-independent death signal in AsPC-1 cells,
we initially tested the level of p53 protein in this pancreatic
cancer cell line. The Western blot with p53 antibody, which
recognizes both mutant and functional forms of p53, failed to
detect p53 proteins in AsPC-1 cells. This observation does
not necessarily rule out the presence of functional (wild-type)
p53 because it is difficult to detect wild-type p53 without
induction by doxorubicin [25]. Surprisingly, treatment of
AsPC-1 cells with doxorubicin was without any effect on
induction of p53 (Figure 4, Panel A) in contrary to the func-
tional p53-positive melanoma cell line, SK Mel 147 (Figure 4,
Panel B).
Because previous observation suggested that the pres-
ence of functional p53 is critical in determining LKB1-
mediated apoptotic response, we thought perhaps a
functional p53 homologue like p73 might be involved in
AsPC-1 cells to augment apoptosis by LKB1. Indeed, p73
was inducible in AsPC-1 cells following doxorubicin treat-
ment (Figure 4, Panel C). Based on this, we propose that
p73, the kin of p53, might be required to activate LKB1-
mediated cell death in AsPC-1 cells.
Discussion
To summarize, our investigation establishes the role of
LKB1 in apoptosis using the LKB1 null pancreatic cancer
cell as a model. The enforced expression of LKB1 can
induce apoptosis in AsPC-1 cells in a mitochondria-
dependent pathway through cytochrome c release. Appa-
rently, the interaction between the p53 homologue, p73,
and LKB1 might facilitate programmed cell death in this
cell line lacking p53. p73 bears significant sequence and
functional similarities to p53. p73 isoform is capable of
activating p53-responsive genes such as WAF1/Kip1 and
Bax; therefore, like p53, it can regulate growth arrest and
cell death. p73 might also be expected to have tumor-
suppressor function and can substitute for p53, when it is
deleted. Clearly, further investigation to demonstrate the
interaction of p73 and LKB1 in AsPC-1 cells is warranted.
Nonetheless, our initial observation reporting the ability of
LKB1 gene to permit pancreatic adenocarcinoma cells to
die by apoptosis is quite important with respect to its
clinical significance. Our studies are concordant with the
previous reports describing the reduced extent of apop-
totic cells in polyps arising from Peutz–Jegher patients
devoid of LKB1 expression.
Cancer of the pancreas stands out as a highly lethal
disease with the poorest likelihood of survival among all of
the major malignancies. The development of malignancies
is a multistep process that comprises initiation, progres-
sion, invasion, and, finally, establishment of metastasis
[26,27]. The multiple genetic alterations at each stage
impart selective advantage over normal counterpart. In
this respect, pancreatic carcinoma is no exception
[28,29]. During the last decade, several cancer-causing
genes including LKB1/STK11 and SMAD4/DPC4 have
been found to be associated with pancreatic carcinoma
[30]. SMAD4, the cytoplasmic messenger of the TGF-h
signal, can associate with LKB1 through an LKB1-inter-
acting protein, LIP1 [31]. It has been previously reported
that the inhibition of LKB1 can suppress TGF-h signaling.
It remains to be seen whether inactivation of LKB1 in the
pancreatic cancer cell line, AsPC-1, leads to the down-
regulation of TGF-h signal, causing suppression of growth
inhibition and apoptosis. Interestingly, AsPC-1 cells are
insensitive to apoptosis in response to the tubulin-binding
drug, 2-methoxyestradiol (Qanungo and Basu, unpub-
lished observation) [32]. Thus, the function of LKB1 in
inducing apoptosis in a subpopulation of pancreatic cancer
cells may uphold the future promise for potential thera-
peutic advantage.
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